$LIXT News

Last published 4mo ago

4mo agoNMAD LIXT FLNC GEV+2AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMADPR NewswireThe artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding power faster than the grid...
4mo agoLIXT LIXTW NMADLIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMADGlobeNewswire-- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026
4mo agoLIXT LIXTWLIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMSGlobeNewswire-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name
4mo agoLIXT LIXTWLIXTE Joins Russell Microcap IndexGlobeNewswireBOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today announced its inclusion in the Russell Microcap® Index, effective
4mo agoBE EOSE FLNC LIXT+1A Nasdaq Company Just Reinvented Itself as a Power Company — and Bet It All on the AI Energy CrunchGlobeNewswireIssued on behalf of LIXTE Biotechnology Holdings, Inc. Having entered into definitive documents to combine with NOMAD, LIXTE is set to become NOMAD Power Solutions — a pure-play deployable-power company aimed squarely
4mo agoBE EOSE FLNC LIXT+1The AI Boom's Real Bottleneck Is Power — and One Nasdaq Company Is Reinventing Itself to Solve ItGlobeNewswireIssued on behalf of LIXTE Biotechnology Holdings, Inc. Having entered into definitive documents to combine with NOMAD, LIXTE is set to become NOMAD Power Solutions — a pure-play deployable-power company — and is
4mo agoLIXT LIXTWLIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026GlobeNewswireCompany to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol BOCA RATON, Fla. &
5mo agoBE EOSE FLNC LIXT+1The New Bottleneck Isn't Computing Power — It's Just PowerGlobeNewswireIssued on behalf of LIXTE Biotechnology Holdings, Inc. America can build data centers in months, but the electricity to run them can take half a decade to arrive. That gap is becoming one of the biggest investment
5mo agoLIXT GEV VST TLN+1From Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power CrunchPR NewswireUSA News Group News Commentary — Corporate reinventions are common; total transformations are rare. Companies pivot products, enter adjacent markets, ...
5mo agoLIXT LIXTWLIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)GlobeNewswireCompany to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar Power Capacity Opportunity BOCA RATON, Fla. & WATERBURY, Vt., June
5mo agoLIXT LIXTWLIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic GrowthGlobeNewswireAnnouncement Follows the Recent Appointment of Denham Capital Founder Stuart D. Porter — a Three-Decade Energy and Infrastructure Investor — to the Company's Board of Directors BOCA RATON, FLA, June 03, 2026 (GLOBE
5mo agoLIXT LIXTWLIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of DirectorsGlobeNewswireBringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure BOCA RATON,
6mo agoLIXT LIXTWLIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress UpdateGlobeNewswireBOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer
7mo agoLIXT LIXTWFavorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care ConferenceGlobeNewswire-Trial Combines LIXTE's LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology
7mo agoLIXT LIXTWLIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative YearGlobeNewswireBOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer
8mo agoLIXT LIXTWLIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. SubsidiaryGlobeNewswireBOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer
9mo agoLIXT LIXTWDE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGEGlobeNewswireEvent Sponsored by LIXTE Biotechnology Holdings,Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the
9mo agoLIXT LIXTWLIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29GlobeNewswireBOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of
10mo agoLIXTIBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.GlobeNewswireAUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- via IBN – LIXTE Biotechnology Holdings Inc. (NASDAQ:LIXT), a biotech company focused on advancing cancer treatments, has engaged IBN, a multifaceted financial news and
10mo agoLIXT LIXTWLIXTE and its Collaborators Expand Clear Cell Ovarian Cancer TrialGlobeNewswire--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the
10mo agoLIXTSpartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct OfferingGlobeNewswireNew York, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, announces its role as exclusive placement agent in a $4.3 million registered direct offering for
10mo agoLIXT LIXTWLixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesGlobeNewswireBOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) (the "Company"), a biotech company focused on advancing cancer treatments, today announced that it has entered into
11mo agoLIXTLIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary ModalitiesACCESS NewswireBOCA RATON, FL / ACCESS Newswire / December 8, 2025 / In recent years, LIXTE has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic angles for resistant
11mo agoLIXTLIXTE Levels Up From PP2A Innovation to Multi-Modal OncologyACCESS NewswireBOCA RATON, FL / ACCESS Newswire / December 3, 2025 / For a micro-cap biotech, the usual headlines bounce between cash raises, compliance updates, and board-room reshuffles. Once in a while, though, one surfaces that
11mo agoLIXTLIXTE Steps Into a Key Role in the Rise of Treatment AmplifiersACCESS NewswireBOCA RATON, FL / ACCESS Newswire / December 3, 2025 / Oncology has spent decades chasing the next magic bullet. The twist is that the next breakthrough may not be a bullet at all. It may be an amplifier, the kind of drug
11mo agoLIXT LIXTWLIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer TreatmentGlobeNewswireLocated at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE
1y agoLIXT LIXTWLIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3GlobeNewswireBOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT, LIXTW)), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class
1y agoLIXT LIXTWLIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition PlansGlobeNewswireCompany underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.
1y agoLIXTLIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)ACCESS NewswireBOCA RATON, FL / ACCESS Newswire / September 16, 2025 / For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spotlight shifts to the
1y agoLIXTLIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)ACCESS NewswireBOCA RATON, FL / ACCESS Newswire / September 15, 2025 / For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings had other
1y agoLIXT LIXTWLIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential AcquisitionsGlobeNewswireBOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced it has made an initial purchase
1y agoLIXT LIXTWLIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial OfficerGlobeNewswire-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage
1y agoLIXT24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer TherapyGlobeNewswireDENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, highlights the publication of a new
1y agoLIXT24/7 Market News: LIXTE Targets Large, Unmet Oncology MarketsGlobeNewswireDENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits LIXTE Biotechnology Holdings,
1y agoLIXT24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the "Too Much of a Good Thing" Strategy for LB-100GlobeNewswireDENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings,
1y agoLIXT LIXTWLIXTE Biotechnology Holdings Provides Corporate UpdateGlobeNewswire-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- -Reports
1y agoLIXT24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025GlobeNewswireBreakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information on Previously issued
1y agoLIXT24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025GlobeNewswireDENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings
1y agoLIXT24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury StrategyGlobeNewswireDENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that LIXTE Biotechnology Holdings
1y agoLIXT LIXTWLIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include CryptocurrencyGlobeNewswirePASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that its Board of Directors has
1y agoLIXT LIXTWLIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing RequirementsGlobeNewswirePASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced it has received a letter from
1y agoLIXT LIXTWLixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the MarketGlobeNewswirePASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) (the "Company"), a clinical stage pharmaceutical company, today announced the closing of a private placement with
1y agoLIXT LIXTWLixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the MarketGlobeNewswirePASADENA, CALIF, July 01, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) (the "Company"), a clinical stage pharmaceutical company, today announced that, on June 30, 2025 intraday, it entered
1y agoLIXT LIXTWLIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100GlobeNewswirePre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE's Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE
1y agoLIXT LIXTWLIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal CancerGlobeNewswire-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on
1y agoLIXT LIXTWNew Findings Show how LIXTE's Lead Clinical Compound, LB-100, is Metabolized to its Active FormGlobeNewswire-- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE"
1y agoLIXT LIXTWLIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell CancerGlobeNewswire-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE's LB-100 in Combination with GSK's Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings,
1y agoLIXT LIXTWLIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswirePASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced the closing of its previously
1y agoLIXT LIXTWLIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswirePASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that it has entered into
1y agoLIXT LIXTWLIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration StatementGlobeNewswirePASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that it has filed a request for